Research & Development
QuVa Pharma unveils the intravenous dexamethasone in support of hospitalized COVID-19 Patients
16 October 2020 -

Healthcare facility QuVa Pharma stated on Thursday the it will supply the Dexamethasone Phosphate as a compounded sterile product in ready-to-administer in 6mg in 25ml 0.9% sodium chloride IV bag for critically-ill Covid-19 patients under FDA Drug Shortage guidelines.

The company added that the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel and the World Health Organization (WHO) updated their recommendations to include systemic corticosteroids, including Dexamethasone 6mg daily, for hospitalized patients with severe and critical COVID-19.

Follow the results of the UK RECOVERY trial, the European Medicines Agency's drug evaluation committee, CHMP, has endorsed Dexamethasone use, 6mg once per day for up to ten days, for hospitalized COVID-19 patients who require oxygen, stated the company.

COVID-19 demonstrates how a uniquely positioned 503B services platform like QuVa can quickly respond to hospitals' pharmaceutical needs and support them in improving patient care, according to its co-founder and CDO Peter Jenkins.



Related Headlines